Praxis Precision Medicines, Inc. PRAX AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s AFS securities?
- Praxis Precision Medicines, Inc. (PRAX) reported AFS securities of $660.94M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s AFS securities changed year-over-year?
- Praxis Precision Medicines, Inc.'s AFS securities increased by 358.9% year-over-year, from $144.03M to $660.94M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s AFS securities?
- Over 3 years (2021 to 2025), Praxis Precision Medicines, Inc.'s AFS securities has grown at a 118.0% compound annual growth rate (CAGR), from $31.53M to $326.76M.